PropThink: No Launch Yet for AMRN's Vascepa is Good News; NCE Decision Is The Next Key Event
(Thomson Reuters ONE) -
By David Moskowitz
Earnings for Amarin Corp. (NASDAQ:AMRN) were primarily focused on the company's
strategy for the launch of Vascepa, as well as the FDA's decision on whether the
newly approved product will have either NCE or NPE exclusivity (5-year or 3-
year regulatory exclusivity, respectively). (See PropThink's prior story.)
Shares are trading higher Friday morning as the company indicated on its
earnings call last night that it is holding back on launching the drug so that
it can finalize discussions with large cap drug companies, which are potential
Vascepa marketing partners or acquirers of the business. Investors were pleased
to see that the company will not launch the drug on its own, at least for now,
which was the risk going into the earnings call. The relief rally today is
likely due to some short covering after the earnings call.
NCE status is key, according to the company. Still, there is risk on the
approaching NCE/NPE decision, and while the company has significantly increased
its intellectual property around Vascepa with multiple new patents protecting
the drug out to ~2030, management admitted on its earnings call that the FDA
decision is a gating factor in discussions with potential strategic
partners/acquirers. We believe NCE has importance, not so much for the
exclusivity protection, but because FDA determining that Vascepa is truly a New
Chemical Entity (NCE) strengthens the overall patent estate on the drug. Without
it, Vascepa's intellectual property position is weaker and is subject to earlier
generic company patent challenges. The next update by the FDA for its 'Orange
Book' is expected on or about November 16th, and that is when we expect to find
out whether or not Vascepa has been designated NCE or NPE exclusivity. Notably,
AMRN stated in its 10-Q that the FDA has drafted a response to the NCE request,
and that response is being circulated around the agency for final decision.
Long bias on AMRN; using options to hedge can help offset the binary risk in the
stock. Expect AMRN to end the day higher, but the risk of the NCE decision could
cap the upside. The expectations of investors we spoke with suggest that AMRN
could trade as high as $16-$18 if Vascepa gains NCE exclusivity, on speculation
that an acquisition will occur before year-end (the Street's $23 price target is
indicative of the value of a real take-out offer). On the other hand, if the FDA
grants NPE status (New Product Exclusivity), AMRN could trade down to the $7.00-
$8.00 range, as investors will assume that no deal is coming and that the
company will have to launch the drug itself, a costly and risk-laden endeavor.
The range of volatility around this key issue means that using an options
strategy around a core position in AMRN makes the most sense, as we have stated
in the past. Our view is that NCE status will be granted, and the FDA taking
more time in making its decision appears to favor that view. Nevertheless, the
decision is a binary risk and investors should proceed accordingly.
See this article in its original publication.
About PropThink
PropThink is an intelligence service that delivers long and short trading ideas
to investors in the healthcare and life sciences sectors. Our focus is on
identifying and analyzing technically-complicated companies and equities that
are grossly over or under-valued. We offer daily market coverage, weekly feature
stories, and a newsletter to investors who subscribe on PropThink.com. To learn
more, follow us on Twitter or visit us at http://www.propthink.com.
Disclaimer:
You should assume that as of the publication date of any report or letter,
PropThink, LLC and persons or entities with whom it has relation ships
(collectively referred to as "PropThink") has a position in all stocks (and/or
options of the stock) covered herein that is consistent with the position set
forth in our research report. Following publication of any report or
letter, PropThink intends to continue transacting in the securities covered
herein, and we may be long, short, or neutral at any time hereafter regardless
of our initial recommendation. To the best of our knowledge and belief, all
information contained herein is accurate and reliable, and has been obtained
from public sources we believe to be accurate and reliable, and not from company
insiders or persons who have a relationship with company insiders. PropThink was
not compensated to publish this article. Our full disclaimer is available
at http://www.propthink.com/disclaimer.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: PropThink via Thomson Reuters ONE
[HUG#1656754]
Unternehmensinformation / Kurzprofil:
Datum: 09.11.2012 - 15:41 Uhr
Sprache: Deutsch
News-ID 201699
Anzahl Zeichen: 5513
contact information:
Town:
New York
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 282 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"PropThink: No Launch Yet for AMRN's Vascepa is Good News; NCE Decision Is The Next Key Event"
steht unter der journalistisch-redaktionellen Verantwortung von
PropThink (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
